UBS Adjusts Price Target on BioNTech
UBS has lowered its price target for BioNTech SE from $135 to $125 while maintaining a "Buy" rating.
Stocks · News reference
Reports of workplace culture concerns and sexism allegations at BioNTech
BioNTech is facing reports of internal workplace culture concerns, including allegations of sexism and complaints from the works council regarding toxic work environments.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Penn-BioNTech Innovative Therapeutics Seed Fund Announces First Investment in Emvena Therapeutics
The Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund), a venture capital fund formed by the University of Pennsylvania and BioNTech SE, has made its inaugural investment in Emvena Therapeutics.
BioNTech Exercises Option Assigning Future R&D Costs Of Roche/Genentech mRNA Program To Roche From Jan. 1, 2027; Eligible For Royalties
BioNTech Repurchased 5.04M ADSs For $463.3M At Avg. $91.98 Through Sept. 30
BioNTech Q3 Cash, Equivalents & Security Investments €16.2B
BioNTech Q3 Adj. EPS €1.76 vs €3.11 YoY; IFRS EPS €0.73 vs Loss €(0.12)